Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

用于肺癌快速早期诊断的血清生物标志物组合

卷 23, 期 7, 2023

发表于: 07 April, 2023

页: [534 - 546] 页: 13

弟呕挨: 10.2174/1568009622666220523154333

价格: $65

conference banner
摘要

背景：肺癌是大多数国家癌症死亡的主要原因。虽然早期诊断和治疗对预后有重大影响，但肺癌通常只在疾病的晚期发现。 目的：广泛使用的筛查和诊断方法不适用于预防性筛查，需要基于血清生物标志物的高通量技术。 方法：筛选501份血清样本，其中肺癌（LC）224份，疾病对照（DC）126份，健康供体（HC）样本151份，寻找新的血清自身抗体作为肺癌早期诊断的生物标志物。在I期，我们使用HuProtTM微阵列对24个LC和24个HC样品进行了初步血清抗体筛选。在II期，我们使用由I期筛选出的22种候选自身抗体生物标志物构建的聚焦阵列筛选了60个LC，60个DC和60个HC血清样品。 结果：经过数据建模和验证，我们选择了四种潜在的早期LC蛋白生物标志物候选物IL2RB，CENPB，TP53和XAGE1A，个体特异性>90%，灵敏度范围为21.2%至32.2%。这四种生物标志物组合在一个组合中时，对早期LC的特异性为>90%，敏感性为>65.5%。使用ELISA测定和273份血清样品（140 LC，66 DC和67 HC）进一步评估这四种候选生物标志物，得出了相似的结果（特异性为>91.7%，灵敏度>61.43%）。 结论：IL2RB、CENPB、TP53和XAGE1A联合生物标志物组合具有快速筛查和改善早期LC诊断的潜力，从而有可能改善其预后。

关键词: 肺癌，快速早期诊断，生物标志物，血清，微阵列，ELISA治疗。

« Previous Next »
图形摘要

[1]
Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, 136(5), E359-E386.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[2]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[3]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[4]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin., 2017, 67(1), 7-30.
[http://dx.doi.org/10.3322/caac.21387] [PMID: 28055103]
[5]
Cao, M.; Chen, W. Epidemiology of lung cancer in China. Thorac. Cancer, 2019, 10(1), 3-7.
[http://dx.doi.org/10.1111/1759-7714.12916] [PMID: 30485694]
[6]
Wardwell, N.R.; Massion, P.P. Novel strategies for the early detection and prevention of lung cancer. Semin. Oncol., 2005, 32(3), 259-268.
[http://dx.doi.org/10.1053/j.seminoncol.2005.02.009] [PMID: 15988680]
[7]
Goldstraw, P.; Crowley, J.; Chansky, K.; Giroux, D.J.; Groome, P.A.; Rami-Porta, R.; Postmus, P.E.; Rusch, V.; Sobin, L. International association for the study of lung cancer international staging. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol., 2007, 2(8), 706-714.
[8]
Davidson, M.R.; Gazdar, A.F.; Clarke, B.E. The pivotal role of pathology in the management of lung cancer. J. Thorac. Dis., 2013, 5(Suppl. 5), S463-S478.
[PMID: 24163740]
[9]
Mantovani, C.; Novello, S.; Ragona, R.; Beltramo, G.; Giglioli, F.R.; Ricardi, U. Chemo-radiotherapy in lung cancer: State of the art with focus on the elderly population. Ann. Oncol., 2006, 17(Suppl. 2), ii61-ii63.
[http://dx.doi.org/10.1093/annonc/mdj926] [PMID: 16608987]
[10]
Oser, M.G.; Niederst, M.J.; Sequist, L.V.; Engelman, J.A. Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin. Lancet Oncol., 2015, 16(4), e165-e172.
[http://dx.doi.org/10.1016/S1470-2045(14)71180-5] [PMID: 25846096]
[11]
Aberle, D.R.; Berg, C.D.; Black, W.C.; Church, T.R.; Fagerstrom, R.M.; Galen, B.; Gareen, I.F.; Gatsonis, C.; Goldin, J.; Gohagan, J.K.; Hillman, B.; Jaffe, C.; Kramer, B.S.; Lynch, D.; Marcus, P.M.; Schnall, M.; Sullivan, D.C.; Sullivan, D.; Zylak, C.J. National Lung Screening Trial Research Team. The National Lung Screening Trial: overview and study design. Radiology, 2011, 258(1), 243-253.
[http://dx.doi.org/10.1148/radiol.10091808] [PMID: 21045183]
[12]
Henschke, C.I. International Early Lung Cancer Action Program Investigators. Survival of patients with clinical stage I lung cancer diagnosed by computed tomography screening for lung cancer. Clin. Cancer Res., 2007, 13(17), 4949-4950.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-0317] [PMID: 17785541]
[13]
Gohagan, J.K.; Marcus, P.M.; Fagerstrom, R.M.; Pinsky, P.F.; Kramer, B.S.; Prorok, P.C.; Ascher, S.; Bailey, W.; Brewer, B.; Church, T.; Engelhard, D.; Ford, M.; Fouad, M.; Freedman, M.; Gelmann, E.; Gierada, D.; Hocking, W.; Inampudi, S.; Irons, B.; Johnson, C.C.; Jones, A.; Kucera, G.; Kvale, P.; Lappe, K.; Manor, W.; Moore, A.; Nath, H.; Neff, S.; Oken, M.; Plunkett, M.; Price, H.; Reding, D.; Riley, T.; Schwartz, M.; Spizarny, D.; Yoffie, R.; Zylak, C. Lung Screening Study Research Group. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer, 2005, 47(1), 9-15.
[http://dx.doi.org/10.1016/j.lungcan.2004.06.007] [PMID: 15603850]
[14]
Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M.; Sicks, J.D. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med., 2011, 365(5), 395-409.
[http://dx.doi.org/10.1056/NEJMoa1102873] [PMID: 21714641]
[15]
Brenner, D.J.; Hall, E.J. Computed tomography-an increasing source of radiation exposure. N. Engl. J. Med., 2007, 357(22), 2277-2284.
[http://dx.doi.org/10.1056/NEJMra072149] [PMID: 18046031]
[16]
Swensen, S.J.; Jett, J.R.; Hartman, T.E.; Midthun, D.E.; Mandrekar, S.J.; Hillman, S.L.; Sykes, A.M.; Aughenbaugh, G.L.; Bungum, A.O.; Allen, K.L. CT screening for lung cancer: five-year prospective experience. Radiology, 2005, 235(1), 259-265.
[http://dx.doi.org/10.1148/radiol.2351041662] [PMID: 15695622]
[17]
Broodman, I.; Lindemans, J.; van Sten, J.; Bischoff, R.; Luider, T. Serum protein markers for the early detection of lung cancer: A focus on autoantibodies. J. Proteome Res., 2017, 16(1), 3-13.
[http://dx.doi.org/10.1021/acs.jproteome.6b00559] [PMID: 27769114]
[18]
Larsen, J.E.; Minna, J.D. Molecular biology of lung cancer: Clinical implications. Clin. Chest Med., 2011, 32(4), 703-740.
[http://dx.doi.org/10.1016/j.ccm.2011.08.003] [PMID: 22054881]
[19]
Wistuba, I.I.; Gazdar, A.F. Lung cancer preneoplasia. Annu. Rev. Pathol., 2006, 1, 331-348.
[http://dx.doi.org/10.1146/annurev.pathol.1.110304.100103] [PMID: 18039118]
[20]
Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[21]
Zhong, L.; Coe, S.P.; Stromberg, A.J.; Khattar, N.H.; Jett, J.R.; Hirschowitz, E.A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol., 2006, 1(6), 513-519.
[22]
Pan, J.; Song, G.; Chen, D.; Li, Y.; Liu, S.; Hu, S.; Rosa, C.; Eichinger, D.; Pino, I.; Zhu, H.; Qian, J.; Huang, Y. Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach. Mol. Cell. Proteomics, 2017, 16(12), 2069-2078.
[http://dx.doi.org/10.1074/mcp.RA117.000212] [PMID: 29021294]
[23]
Zhang, H.; Zhang, S. Present situation of lung cancer screening methods. Zhongguo Fei Ai Za Zhi, 2016, 19(10), 715-720.
[PMID: 27760605]
[24]
Hu, S.; Wan, J.; Su, Y.; Song, Q.; Zeng, Y.; Nguyen, H.N.; Shin, J.; Cox, E.; Rho, H.S.; Woodard, C.; Xia, S.; Liu, S.; Lyu, H.; Ming, G-L.; Wade, H.; Song, H.; Qian, J.; Zhu, H. DNA methylation presents distinct binding sites for human transcription factors. eLife, 2013, 2, e00726.
[http://dx.doi.org/10.7554/eLife.00726] [PMID: 24015356]
[25]
Hu, C.J.; Pan, J.B.; Song, G.; Wen, X.T.; Wu, Z.Y.; Chen, S.; Mo, W.X.; Zhang, F.C.; Qian, J.; Zhu, H.; Li, Y.Z. Identification of novel biomarkers for Behcet Disease diagnosis using HuProt array approach. Mol. Cell. Proteomics, 2017, 16(2), 147-156.
[http://dx.doi.org/10.1074/mcp.M116.061002] [PMID: 27777341]
[26]
Yang, L.; Wang, J.; Li, J.; Zhang, H.; Guo, S.; Yan, M.; Zhu, Z.; Lan, B.; Ding, Y.; Xu, M.; Li, W.; Gu, X.; Qi, C.; Zhu, H.; Shao, Z.; Liu, B.; Tao, S.C. Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol. Cell. Proteomics, 2016, 15(2), 614-623.
[http://dx.doi.org/10.1074/mcp.M115.051250] [PMID: 26598640]
[27]
Syed, P.; Gupta, S.; Choudhary, S.; Pandala, N.G.; Atak, A.; Richharia, A. K p, M.; Zhu, H.; Epari, S.; Noronha, S.B.; Moiyadi, A.; Srivastava, S. Autoantibody profiling of glioma serum samples to identify biomarkers using human proteome arrays. Sci. Rep., 2015, 5, 13895.
[http://dx.doi.org/10.1038/srep13895] [PMID: 26370624]
[28]
Zhou, Y.; Guo, T.; Tang, G.; Wu, H.; Wong, N.K.; Pan, Z. Site-selective protein immobilization by covalent modification of GST fusion proteins. Bioconjug. Chem., 2014, 25(11), 1911-1915.
[http://dx.doi.org/10.1021/bc500347b] [PMID: 25340706]
[29]
Huang, C.G.; Li, F.X.; Pan, S.; Xu, C.B.; Dai, J.Q.; Zhao, X.H. Identification of genes associated with castration resistant prostate cancer by gene expression profile analysis. Mol. Med. Rep., 2017, 16(5), 6803-6813.
[http://dx.doi.org/10.3892/mmr.2017.7488] [PMID: 28901445]
[30]
Song, G.; Hu, C.; Zhu, H.; Wang, L.; Zhang, F.; Li, Y.; Wu, L. New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays. J. Rheumatol., 2013, 40(4), 461-468.
[http://dx.doi.org/10.3899/jrheum.120264] [PMID: 23418382]
[31]
Tusher, V.G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA, 2001, 98(9), 5116-5121.
[32]
Kanehisa, M.; Furumichi, M.; Tanabe, M.; Sato, Y.; Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res., 2017, 45(D1), D353-D361.
[http://dx.doi.org/10.1093/nar/gkw1092] [PMID: 27899662]
[33]
Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5), 284-287.
[http://dx.doi.org/10.1089/omi.2011.0118] [PMID: 22455463]
[34]
Haakensen, V.D.; Khadse, A.; Sandhu, V.; Halvorsen, A.R.; Solberg, S.K.; Jørgensen, L.H.; Brustugun, O.T.; Kure, E.H.; Helland, Å. Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy. Int. J. Cancer, 2020, 147(10), 2957-2966.
[http://dx.doi.org/10.1002/ijc.33121] [PMID: 32468587]
[35]
Liu, Y.; Wang, M. Advances in early diagnosis of lung cancer. Zhongguo Fei Ai Za Zhi, 2011, 14(5), 429-434.
[PMID: 21569649]
[36]
Jeong, J.S.; Jiang, L.; Albino, E.; Marrero, J.; Rho, H.S.; Hu, J.; Hu, S.; Vera, C.; Bayron-Poueymiroy, D.; Rivera-Pacheco, Z.A.; Ramos, L.; Torres-Castro, C.; Qian, J.; Bonaventure, J.; Boeke, J.D.; Yap, W.Y.; Pino, I.; Eichinger, D.J. Heng, Zhu.; Blackshaw, S. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol. Cell. Proteomics, 2012, 11(6), O111.
[http://dx.doi.org/10.1074/mcp.O111.016253]
[37]
Olivier, M.; Hollstein, M.; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2010, 2(1), a001008.
[http://dx.doi.org/10.1101/cshperspect.a001008] [PMID: 20182602]
[38]
Aubrey, B.J.; Strasser, A.; Kelly, G.L. Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb. Perspect. Med., 2016, 6(5), a026062.
[http://dx.doi.org/10.1101/cshperspect.a026062] [PMID: 27141080]
[39]
Soussi, T. p53 Antibodies in the sera of patients with various types of cancer: A review. Cancer Res., 2000, 60(7), 1777-1788.
[PMID: 10766157]
[40]
Simpson, A.J.; Caballero, O.L.; Jungbluth, A.; Chen, Y.T.; Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer, 2005, 5(8), 615-625.
[http://dx.doi.org/10.1038/nrc1669] [PMID: 16034368]
[41]
Brinkmann, U.; Vasmatzis, G.; Lee, B.; Pastan, I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res., 1999, 59(7), 1445-1448.
[PMID: 10197611]
[42]
Zendman, A.J.; Van Kraats, A.A.; Weidle, U.H.; Ruiter, D.J.; Van Muijen, G.N. The XAGE family of cancer/testis-associated genes: Alignment and expression profile in normal tissues, melanoma lesions and Ewing’s sarcoma. Int. J. Cancer, 2002, 99(3), 361-369.
[http://dx.doi.org/10.1002/ijc.10371] [PMID: 11992404]
[43]
Egland, K.A.; Kumar, V.; Duray, P.; Pastan, I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol. Cancer Ther., 2002, 1(7), 441-450.
[PMID: 12479262]
[44]
Nakagawa, K.; Noguchi, Y.; Uenaka, A.; Sato, S.; Okumura, H.; Tanaka, M.; Shimono, M.; Ali Eldib, A.M.; Ono, T.; Ohara, N.; Yoshino, T.; Yamashita, K.; Tsunoda, T.; Aoe, M.; Shimizu, N.; Nakayama, E. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin. Cancer Res., 2005, 11(15), 5496-5503.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0216] [PMID: 16061866]
[45]
Waldmann, T.A. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat. Rev. Immunol., 2006, 6(8), 595-601.
[http://dx.doi.org/10.1038/nri1901] [PMID: 16868550]
[46]
Leonard, W.J.; Depper, J.M.; Crabtree, G.R.; Rudikoff, S.; Pumphrey, J.; Robb, R.J.; Krönke, M.; Svetlik, P.B.; Peffer, N.J.; Waldmann, T.A. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature, 1984, 311(5987), 626-631.
[http://dx.doi.org/10.1038/311626a0] [PMID: 6090948]
[47]
Wang, X.; Lupardus, P.; Laporte, S.L.; Garcia, K.C. Structural biology of shared cytokine receptors. Annu. Rev. Immunol., 2009, 27, 29-60.
[http://dx.doi.org/10.1146/annurev.immunol.24.021605.090616] [PMID: 18817510]
[48]
Fernandez, I.Z.; Baxter, R.M.; Garcia-Perez, J.E.; Vendrame, E.; Hsieh, E.W.Y. Correction: A novel human IL2RB mutation results in T and NK cell-driven immune dysregulation. J. Exp. Med., 2019, 216(6), 1465.
[http://dx.doi.org/10.1084/jem.2018201505102019c]
[49]
Garaci, E.; Sinibaldi, P.; Rasi, G. A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP)--a possible new tumor marker. Anticancer Res., 1996, 16(4B), 2253-2255.
[PMID: 8694552]
[50]
Pan, J.; Yu, L.; Wu, Q.; Lin, X.; Liu, S.; Hu, S.; Rosa, C.; Eichinger, D.; Pino, I.; Zhu, H.; Qian, J.; Huang, Y. Integration of IgA and IgG autoantigens improves performance of biomarker panels for early diagnosis of lung cancer. Mol. Cell. Proteomics, 2020, 19(3), 490-500.
[http://dx.doi.org/10.1074/mcp.RA119.001905] [PMID: 31924693]
[51]
Türeci, O.; Mack, U.; Luxemburger, U.; Heinen, H.; Krummenauer, F.; Sester, M.; Sester, U.; Sybrecht, G.W.; Sahin, U. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett., 2006, 236(1), 64-71.
[http://dx.doi.org/10.1016/j.canlet.2005.05.008] [PMID: 15992994]
[52]
Chapman, C.J.; Murray, A.; McElveen, J.E.; Sahin, U.; Luxemburger, U.; Türeci, O.; Wiewrodt, R.; Barnes, A.C.; Robertson, J.F. Autoantibodies in lung cancer: Possibilities for early detection and subsequent cure. Thorax, 2008, 63(3), 228-233.
[http://dx.doi.org/10.1136/thx.2007.083592] [PMID: 17932110]
[53]
Chapman, C.J.; Healey, G.F.; Murray, A.; Boyle, P.; Robertson, C.; Peek, L.J.; Allen, J.; Thorpe, A.J.; Hamilton-Fairley, G.; Parsy-Kowalska, C.B.; MacDonald, I.K.; Jewell, W.; Maddison, P.; Robertson, J.F. EarlyCDT®-Lung test: Improved clinical utility through additional autoantibody assays. Tumour Biol., 2012, 33(5), 1319-1326.
[http://dx.doi.org/10.1007/s13277-012-0379-2] [PMID: 22492236]

Rights & Permissions Print Cite
Article Metrics
59
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy